Literature DB >> 22512363

Methadone and buprenorphine for the management of opioid dependence in pregnancy.

Hendrée E Jones1, Loretta P Finnegan, Karol Kaltenbach.   

Abstract

This article provides an overview and discussion of the collective maternal, fetal and neonatal outcome research on women maintained on methadone or buprenorphine during pregnancy. Its focus is on an assessment of the comparative effectiveness of methadone and buprenorphine pharmacotherapy, with particular attention given to recent findings from the literature. Recommendations for clinical practice are outlined, and directions for future research are presented. Findings from comparative studies of methadone and buprenorphine underscore the efficacy of both medications in preventing relapse to illicit opioid use in the treatment of opioid-dependent pregnant patients, as well as the simplicity of induction onto methadone and patient retention while receiving such therapy. Fetal monitoring suggests that buprenorphine results in less fetal cardiac and movement suppression than does methadone. The clinical implications of these findings need future exploration. For the neonate, evidence from studies using a wide range of designs, including retrospective chart reviews, prospective observational studies, and randomized clinical trials, show consistent results, with prenatal exposure to buprenorphine resulting in less severe neonatal abstinence syndrome relative to methadone. Any medication given to pregnant women should be prescribed only after considering the risk : benefit ratio for the maternal-fetal dyad. Medication choices for each opioid-dependent patient during pregnancy need to be made on a patient-by-patient basis, taking into consideration the patient's opioid dependence history, previous and current treatment experiences, medical circumstances and treatment preferences. Moreover, for a full remission of opioid addiction to be sustainable, both post-partum and across the lifespan, treatment providers must not rely solely on medication to treat their patients but should also utilize women-specific comprehensive treatment models that address the underlying multifaceted complexities of their patient's lives.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512363     DOI: 10.2165/11632820-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  68 in total

1.  Relationship between maternal methadone dosage and neonatal withdrawal.

Authors:  Jodi S Dashe; Jeanne S Sheffield; Debora A Olscher; Sally J Todd; Gregory L Jackson; George D Wendel
Journal:  Obstet Gynecol       Date:  2002-12       Impact factor: 7.661

2.  Neonatal abstinence syndrome: assessment and management.

Authors:  L P Finnegan; J F Connaughton; R E Kron; J P Emich
Journal:  Addict Dis       Date:  1975

3.  The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women.

Authors:  H E Jones; N Haug; K Silverman; M Stitzer; D Svikis
Journal:  Drug Alcohol Depend       Date:  2001-02-01       Impact factor: 4.492

4.  Methadone and perinatal outcomes: another perspective.

Authors:  Hendrée E Jones; Lauren M Jansson; Karol Kaltenbach
Journal:  Am J Obstet Gynecol       Date:  2011-06-15       Impact factor: 8.661

Review 5.  Exposure to opiates: behavioral outcomes in preschool and school-age children.

Authors:  K A Kaltenbach
Journal:  NIDA Res Monogr       Date:  1996

6.  Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH.

Authors:  F A Manning; R Snijders; C R Harman; K Nicolaides; S Menticoglou; I Morrison
Journal:  Am J Obstet Gynecol       Date:  1993-10       Impact factor: 8.661

7.  The effect of methadone and buprenorphine on human placental aromatase.

Authors:  Olga L Zharikova; Sujal V Deshmukh; Tatiana N Nanovskaya; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biochem Pharmacol       Date:  2006-02-07       Impact factor: 5.858

8.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.

Authors:  Hendree E Jones; Rolley E Johnson; Donald R Jasinski; Kevin E O'Grady; Christian A Chisholm; Robin E Choo; Michael Crocetti; Robert Dudas; Cheryl Harrow; Marilyn A Huestis; Lauren M Jansson; Michael Lantz; Barry M Lester; Lorraine Milio
Journal:  Drug Alcohol Depend       Date:  2005-07       Impact factor: 4.492

9.  Is opiate detoxification unsafe in pregnancy?

Authors:  Jason Luty; Vasilis Nikolaou; Jenny Bearn
Journal:  J Subst Abuse Treat       Date:  2003-06

10.  Using naltrexone implants in the management of the pregnant heroin user.

Authors:  G Hulse; G O'Neil
Journal:  Aust N Z J Obstet Gynaecol       Date:  2002-11       Impact factor: 2.100

View more
  32 in total

1.  Recent trends in treatment admissions for prescription opioid abuse during pregnancy.

Authors:  Caitlin E Martin; Nyaradzo Longinaker; Mishka Terplan
Journal:  J Subst Abuse Treat       Date:  2014-07-23

Review 2.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  Factors associated with buprenorphine versus methadone use in pregnancy.

Authors:  Elizabeth E Krans; Debra Bogen; Gale Richardson; Seo Young Park; Shannon L Dunn; Nancy Day
Journal:  Subst Abus       Date:  2016-02-25       Impact factor: 3.716

Review 4.  Opioid Use Disorder in Pregnancy: Health Policy and Practice in the Midst of an Epidemic.

Authors:  Elizabeth E Krans; Stephen W Patrick
Journal:  Obstet Gynecol       Date:  2016-07       Impact factor: 7.661

5.  Novel biomarkers to assess in utero effects of maternal opioid use: First steps toward understanding short- and long-term neurodevelopmental sequelae.

Authors:  Laura Goetzl; Tara Thompson-Felix; Nune Darbinian; Nana Merabova; Salim Merali; Carmen Merali; Kathryne Sanserino; Tamara Tatevosian; Bruno Fant; Mathieu E Wimmer
Journal:  Genes Brain Behav       Date:  2019-06-11       Impact factor: 3.449

Review 6.  The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care.

Authors:  Jason R Pryor; Faouzi I Maalouf; Elizabeth E Krans; Robert E Schumacher; William O Cooper; Stephen W Patrick
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2017-01-10       Impact factor: 5.747

7.  Commentary on Mactier et al. (2014): Methadone-assisted treatment and the complexity of influences on fetal development.

Authors:  Hendrée E Jones; Mishka Terplan; Catherine J Friedman; James Walsh; Lauren M Jansson
Journal:  Addiction       Date:  2014-03       Impact factor: 6.526

8.  Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas.

Authors:  Marjorie Meyer; Julie Phillips
Journal:  Prev Med       Date:  2015-07-26       Impact factor: 4.018

Review 9.  Buprenorphine use in pregnant opioid users: a critical review.

Authors:  Michael Soyka
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

10.  Managing infants born to mothers who have used opioids during pregnancy.

Authors:  Thierry Lacaze-Masmonteil; Pat O'Flaherty
Journal:  Paediatr Child Health       Date:  2018-05-11       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.